For the Quarter Ending June 2026
Lorazepam Prices in North America
- In the United States, the Lorazepam Price Index rose quarter-over-quarter in Q2 2026, driven by significant producer inflation.
- Lorazepam production costs increased due to producer price inflation of 5.5% year-over-year in June 2026.
- Demand for Lorazepam was supported by U.S. pharmaceutical market growth and expanding neurology therapies in Q2 2026.
- Strong retail sales, up 6.9% in May 2026, and low 4.2% unemployment in June 2026 bolstered patient affordability.
- Consumer confidence remained moderate at 91.2 in June 2026, supporting a stable environment for healthcare spending.
- Elevated Brent crude oil prices in Q2 2026, peaking in April, impacted energy and feedstock expenses.
- US chemical exports trended upward in Q2 2026, while imports continued to decline during the quarter.
- Overall Industrial Production in the United States inched up in June 2026, expanding at a solid annual rate.
- The Life Sciences sector maintained an optimistic outlook in Q2 2026, supporting a stable Lorazepam price forecast.
Why did the price of Lorazepam change in June 2026 in North America?
- Producer price inflation, up 5.5% in June 2026, significantly increased Lorazepam manufacturing costs.
- Elevated Brent crude oil prices in Q2 2026, peaking in April, raised energy and feedstock expenses.
- Robust retail sales, up 6.9% in May 2026, supported demand, counteracting 3.5% consumer inflation.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index rose quarter-over-quarter in Q2 2026, driven by increasing production costs and robust demand.
- Lorazepam production costs increased in Q2 2026, influenced by a 4.1% rise in the Producer Price Index in June 2026.
- Demand for pharmaceuticals in China strengthened in 2026, propelled by an aging population and rising chronic illnesses.
- Higher feedstock costs for pharmaceutical intermediates in Q2 2026 resulted from export tax rebate removal effective April 1, 2026.
- China's Manufacturing Index expanded in June 2026, supporting overall pharmaceutical production and supply chain.
- Industrial production increased by 5.3% year-over-year in June 2026, ensuring stable supply of chemical intermediates.
- A stable 5.0% unemployment rate in June 2026 supported patient access to healthcare and medication affordability.
- Retail sales growth was low at 1.0% year-over-year in June 2026, indirectly influencing patient medication affordability.
- Healthcare spending per capita increased in 2026, while government health expenditure decreased in May 2026.
Why did the price of Lorazepam change in June 2026 in APAC?
- Rising Producer Price Index (4.1% in June 2026) increased raw material and API costs.
- Higher feedstock costs in Q2 2026 resulted from export tax rebate removal.
- Strengthened pharmaceutical demand in China in 2026 supported the upward price trend.
Lorazepam Prices in Europe
- In Germany, the Lorazepam Price Index rose quarter-over-quarter in Q2 2026, driven by significant production cost increases.
- Lorazepam production costs climbed due to a 2.2% rise in producer prices in May 2026 and elevated energy and raw material costs.
- Lorazepam demand was mixed; consumer confidence was -14.6% in June 2026, while retail sales rose 1.8% in May 2026.
- The Manufacturing Index contracted in June 2026; industrial production was 0.0% in May 2026, impacting supply chain inputs.
- General inflation, with CPI at 2.3% in June 2026, raised operational costs for Lorazepam manufacturers.
- A stable unemployment rate of 3.8% in May 2026 supported healthcare affordability, influencing Lorazepam demand.
- Precautionary stockpiling, influenced by Persian Gulf tensions, affected Lorazepam inventory levels in Q2 2026.
- The Lorazepam Price Forecast suggests continued upward pressure due to persistent high input costs and supply chain strains.
Why did the price of Lorazepam change in June 2026 in Europe?
- Producer prices for industrial products rose by 2.2% in May 2026, increasing Lorazepam manufacturing costs.
- Elevated energy and raw material costs in Q2 2026 directly impacted Lorazepam production expenses.
- Temporary demand shifts to German suppliers in June 2026, due to Middle East supply disruptions, supported prices.
For the Quarter Ending March 2026
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q1 2026, driven by elevated production costs.
- The Lorazepam Production Cost Trend increased in March 2026 as the Producer Price Index rose 4.0%.
- The Lorazepam Demand Outlook strengthened in March 2026, supported by a 3.3% Consumer Price Index increase.
- Retail sales grew 4.0% and unemployment reached 4.3% in March 2026, sustaining Lorazepam prescription affordability.
- Industrial production grew 0.7% and the Manufacturing Index expanded in March 2026, supporting Lorazepam supply chains.
- Benzene feedstock and natural gas costs surged in January 2026, directly elevating the Lorazepam Price Index.
- The Lorazepam Price Forecast remained upward in Q1 2026 due to tightened injectable supply and manufacturing delays.
Why did the price of Lorazepam change in March 2026 in North America?
- Elevated patient demand for anxiety treatments drove Lorazepam prescription volumes significantly higher throughout Q1 2026.
- International supply chain issues and pharmaceutical ingredient sourcing delays slowed domestic production in Q1 2026.
- Natural gas prices and benzene feedstock costs rose sharply in January 2026, increasing manufacturing expenses.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index rose quarter over quarter in Q1 2026, reflecting upstream feedstock surges.
- The Lorazepam Production Cost Trend increased in March 2026 as upstream crude oil and naphtha prices surged.
- A 0.5% Producer Price Index rise in March 2026 elevated manufacturing expenses for Lorazepam chemical precursors.
- The Lorazepam Demand Outlook expanded in Q1 2026, supported by a 1.0% Consumer Price Index increase.
- The Manufacturing Index expanded in March 2026, while industrial production grew 5.7%, ensuring steady Lorazepam supply.
- Slower retail sales growth of 1.7% in March 2026 marginally reduced pharmacy foot traffic for treatments.
- The Lorazepam Price Forecast remained elevated in Q1 2026 as buyers sought alternative Middle Eastern cargoes.
Why did the price of Lorazepam change in March 2026 in APAC?
- Global crude oil markets experienced a massive energy supply shock in March 2026, disrupting stability.
- Naphtha feedstock costs experienced a substantial increase in Q1 2026, elevating benzene value chain expenses.
- Domestic benzene discussion levels surged in March 2026 as buyers scrambled to secure forward cargoes.
Lorazepam Prices in Europe
- In Germany, the Lorazepam Price Index rose quarter-over-quarter in Q1 2026, driven by surging chemical precursor costs.
- The Lorazepam Production Cost Trend increased in March 2026 as 2.7% inflation elevated pharmaceutical manufacturing operational costs.
- Despite producer prices declining 0.2% in March 2026, benzene and ammonia precursor costs surged across the region.
- The Manufacturing Index expanded in March 2026, ensuring stable supply chains for final packaged retail Lorazepam products.
- Industrial production remained stagnant at 0.0% in February 2026, while domestic pharmaceutical output plummeted in January 2026.
- Retail sales grew 0.7% in February 2026, supporting steady consumer spending and retail pharmacy oral Lorazepam purchases.
- The Lorazepam Price Forecast indicated upward pressure in Q1 2026 due to tightened regional ammonia chemical inventories.
Why did the price of Lorazepam change in March 2026 in Europe?
- European spot costs for benzene, a critical Lorazepam feedstock, surged significantly regionally in March 2026.
- Ammonia supply tightened across Europe in March 2026 following widespread regional outages and severe bottlenecks.
- Crude oil prices surged in March 2026, intensifying upstream cost pressures for European petrochemical feedstocks.
For the Quarter Ending December 2025
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q4 2025, driven by rising production costs.
- Lorazepam production costs increased due to a 3.0% year-over-year PPI rise in November 2025, impacting inputs.
- Consumer prices, indicated by a 2.7% year-over-year CPI increase in December 2025, raised general manufacturing expenses.
- Lorazepam demand was supported by a 3.3% year-over-year increase in retail sales in November 2025.
- A 4.4% unemployment rate in December 2025 indicated a strong labor market, enhancing Lorazepam affordability.
- Industrial production increased 2.0% year-over-year in December 2025, supporting pharmaceutical supply chains.
- Manufacturing output declined annually in Q4 2025, reflecting broader US chemical production headwinds.
- Colder weather influenced Henry Hub natural gas spot prices in December 2025; futures softened, reducing supply concerns.
Why did the price of Lorazepam change in December 2025 in North America?
- Rising production costs were driven by a 3.0% year-over-year PPI increase in November 2025, affecting Lorazepam inputs.
- Strong consumer spending, evidenced by a 3.3% year-over-year retail sales increase in November 2025, supported demand.
- Softening Henry Hub natural gas futures prices in December 2025 after an early peak influenced energy costs.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index fell quarter-over-quarter in Q4 2025, driven by declining producer prices.
- Lorazepam production costs declined in December 2025, as producer prices fell 1.9% year-over-year.
- The Lorazepam demand outlook remained subdued in Q4 2025, with retail sales growing 0.9% in December 2025.
- Weak inflationary pressure, with CPI at 0.8% in December 2025, contributed to stable overall healthcare costs.
- Consumer sentiment cooled in Q4 2025, impacting spending, alongside 5.1% unemployment in December 2025.
- Manufacturing activity expanded in December 2025, supported by a 5.2% rise in industrial production.
- Global petrochemical feedstock demand was less robust in 2025, easing Lorazepam production cost pressures.
- China's basic petrochemical supply strengthened in 2025, with increased exports impacting trade flows.
- Oil inventories experienced further builds in December 2025, indicating ample energy supply.
Why did the price of Lorazepam change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing manufacturing costs.
- Subdued overall consumer demand in China in Q4 2025 impacted Lorazepam's market demand.
- Less robust global petrochemical feedstock demand in 2025 contributed to lower input costs.
Lorazepam Prices in Europe
- In Germany, the Lorazepam Price Index fell quarter-over-quarter in Q4 2025, influenced by weak industrial demand in October 2025.
- Lorazepam production costs declined in December 2025, as the Producer Price Index (PPI) decreased by 2.5% year-over-year.
- Operational costs for Lorazepam manufacturers increased in December 2025 due to a 1.8% year-over-year rise in the Consumer Price Index (CPI).
- The Lorazepam demand outlook remained constrained in Q4 2025, with the Manufacturing Index contracting in December 2025.
- Industrial production grew 0.8% year-over-year in October 2025, supporting stable supply chains, while retail sales rose 1.1% in November 2025.
- Consumer confidence remained pessimistic at -17.5 in December 2025, affecting healthcare spending and Lorazepam access.
- Germany's unemployment rate of 6.2% in December 2025 indicated economic slack, potentially straining public healthcare budgets.
- The Lorazepam Price Index is forecast to remain under pressure, given persistent weak demand and high competitive intensity in Q4 2025.
Why did the price of Lorazepam change in December 2025 in Europe?
- Producer Price Index (PPI) decreased by 2.5% year-over-year in December 2025, reducing manufacturing input costs.
- Contracting Manufacturing Index in December 2025 and weak industrial economy weighed on overall chemical demand.
- Increased competitive pressure from abroad forced German chemical companies to lower prices in October 2025.
For the Quarter Ending September 2025
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs and shrinking inventories.
- Rising CPI (3.0% in September 2025) indicated higher operational costs for Lorazepam manufacturers.
- Producer Price Index (2.6% in August 2025) increased raw material costs for Lorazepam production.
- US natural gas prices saw an uptick in Q3 2025, increasing Lorazepam production expenses.
- Chemical manufacturers reported shrinking inventories in Q3 2025 due to accelerating destocking, impacting Lorazepam supply.
- US pharmaceutical exports increased in August 2025, while imports decreased, influencing Lorazepam trade flows.
- Strong retail sales (5.42% in September 2025) supported consumer ability to afford Lorazepam healthcare expenses.
- The low unemployment rate (4.3% in September 2025) enhanced consumer disposable income for Lorazepam access.
- Declining consumer confidence in September 2025 suggested potential constraints on Lorazepam consumer spending.
- Chemical manufacturing economic conditions sentiment deteriorated further during Q3 2025.
Why did the price of Lorazepam change in September 2025 in North America?
- Increased raw material costs, evidenced by the 2.6% PPI rise in August 2025, pressured Lorazepam prices upward.
- Higher operational expenses, indicated by the 3.0% CPI increase in September 2025, contributed to rising Lorazepam costs.
- Shrinking chemical inventories in Q3 2025, coupled with natural gas price upticks, tightened Lorazepam supply.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index fell quarter-over-quarter, influenced by significant production cost reductions.
- Lorazepam production costs decreased in Q3 2025, driven by a -2.3% PPI year-on-year in September 2025.
- Demand for Lorazepam was supported by a 3.0% rise in retail sales year-on-year in September 2025.
- The Lorazepam demand outlook remained robust due to China's aging population and rising chronic diseases.
- China's Manufacturing Index contracted in September 2025, indirectly impacting the broader Lorazepam market.
- Industrial production increased by 6.5% year-on-year in September 2025, supporting healthcare spending.
- Trade flows faced challenges from US tariffs effective August 2025, impacting Lorazepam exports.
- Feedstock costs, including 1,4-Butanediol, weakened in July 2025, contributing to lower production expenses.
- Lower electricity prices in China in 2025 provided a cost advantage for Lorazepam manufacturers.
Why did the price of Lorazepam change in September 2025 in APAC?
- Production costs for Lorazepam decreased due to a -2.3% PPI year-on-year in September 2025.
- Deflationary pressures from a -0.3% CPI year-on-year in September 2025 impacted pharmaceutical pricing.
- Weakening 1,4-Butanediol costs in July 2025 contributed to overall lower Lorazepam production expenses.
Lorazepam Prices in Europe
- In Germany, Lorazepam Price Index fell in Q3 2025, influenced by suppressed feedstock and mixed demand.
- Lorazepam production costs faced downward pressure in Q3 2025, as PPI declined 1.7% in September.
- Rising CPI (2.4% in September 2025) signaled higher operational costs for Lorazepam producers.
- Demand for Lorazepam was moderately supported in Q3 2025 by pharmaceutical market growth and aging.
- Manufacturing Index contracted in September 2025, Industrial Production declining 1.0%, impacting supply.
- Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to persistent oversupply.
- Elevated natural gas and electricity prices in Europe pressured Lorazepam production costs.
- Consumer confidence deteriorated to -23.6 in September 2025, potentially impacting healthcare spending.
- Low unemployment (3.9%) in September 2025 supported consumer affordability for prescription medications.
- Retail sales grew 0.8% in September 2025, indicating slight consumer spending resilience.
Why did the price of Lorazepam change in September 2025 in Europe?
- Producer Price Index declined 1.7% in September 2025, reducing Lorazepam input costs in Europe.
- Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to oversupply, lowering production.
- Elevated natural gas and electricity prices in Q3 2025 increased operational costs for Lorazepam producers.
